Dec. 21 at 11:32 AM
$PMN From the latest press release:
“This is a major execution milestone for ProMIS and a potentially pivotal moment for the Alzheimer’s field” said Neil Warma, CEO of ProMIS Neurosciences. “Completing enrollment and above our target in a rigorously designed, biomarker-rich study of this scale positions us to potentially confirm, clinically and biologically, for the first time the central role of toxic amyloid-beta oligomers in Alzheimer’s disease. The safety profile we have observed thus far, with no treatment-related SAEs and minimal dropouts, reinforces our belief that PMN310 may offer a fundamentally differentiated approach that has the potential to significantly reduce the ARIA liability that has limited broader use of current therapies. We believe the over-enrollment of PRECISE-AD may reflect strong enthusiasm among both patients and trial physicians.....upcoming blinded interim analysis expected in Q2 2026 and final unblinded top-line results expected in Q4 2026.”
